HRP20181213T1 - Peptidna smjesa - Google Patents

Peptidna smjesa

Info

Publication number
HRP20181213T1
HRP20181213T1 HRP20181213TT HRP20181213T HRP20181213T1 HR P20181213 T1 HRP20181213 T1 HR P20181213T1 HR P20181213T T HRP20181213T T HR P20181213TT HR P20181213 T HRP20181213 T HR P20181213T HR P20181213 T1 HRP20181213 T1 HR P20181213T1
Authority
HR
Croatia
Prior art keywords
peptide mixture
peptide
mixture
Prior art date
Application number
HRP20181213TT
Other languages
English (en)
Croatian (hr)
Inventor
Jon Amund Eriksen
Original Assignee
Targovax Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targovax Asa filed Critical Targovax Asa
Publication of HRP20181213T1 publication Critical patent/HRP20181213T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001164GTPases, e.g. Ras or Rho
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
HRP20181213TT 2013-12-09 2014-12-09 Peptidna smjesa HRP20181213T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13196333 2013-12-09
PCT/EP2014/077033 WO2015086590A2 (en) 2013-12-09 2014-12-09 A peptide mixture
EP14828148.8A EP3079715B1 (en) 2013-12-09 2014-12-09 A peptide mixture

Publications (1)

Publication Number Publication Date
HRP20181213T1 true HRP20181213T1 (hr) 2018-10-19

Family

ID=49765823

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181213TT HRP20181213T1 (hr) 2013-12-09 2014-12-09 Peptidna smjesa

Country Status (24)

Country Link
US (4) US9775892B2 (enExample)
EP (5) EP3363458A3 (enExample)
JP (2) JP6781403B2 (enExample)
KR (1) KR20160097290A (enExample)
CN (1) CN105980403A (enExample)
AU (2) AU2014363643B2 (enExample)
BR (1) BR112016013138A2 (enExample)
CA (1) CA2933126A1 (enExample)
CL (4) CL2016001405A1 (enExample)
CY (1) CY1120578T1 (enExample)
DK (1) DK3079715T3 (enExample)
ES (1) ES2682038T3 (enExample)
HR (1) HRP20181213T1 (enExample)
HU (1) HUE039840T2 (enExample)
IL (1) IL246007B2 (enExample)
LT (1) LT3079715T (enExample)
MX (1) MX2016007429A (enExample)
PL (1) PL3079715T3 (enExample)
PT (1) PT3079715T (enExample)
RS (1) RS57623B1 (enExample)
RU (1) RU2016127327A (enExample)
SG (2) SG10201811172PA (enExample)
SI (1) SI3079715T1 (enExample)
WO (1) WO2015086590A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775892B2 (en) 2013-12-09 2017-10-03 Targovax Asa Peptide mixture
CN106414493A (zh) 2014-05-06 2017-02-15 塔格瓦克斯公司 包含突变的ras肽和化疗剂的肽疫苗
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
AU2018288386A1 (en) * 2017-06-22 2020-02-06 New South Wales Health Pathology Adoptive T cell therapy 2
CA3103983A1 (en) * 2018-06-19 2019-12-26 Biontech Us Inc. Neoantigens and uses thereof
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
JP2021534752A (ja) * 2018-08-22 2021-12-16 フレッド ハッチンソン キャンサー リサーチ センター Kras抗原またはher2抗原を標的とする免疫療法
GB2596461B (en) 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
WO2021009633A1 (en) * 2019-07-12 2021-01-21 Massey University Synthetic chromatin vaccine
US12453774B2 (en) 2019-11-07 2025-10-28 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
KR102515083B1 (ko) 2020-12-24 2023-03-29 부산대학교 산학협력단 폴더블 페로브스카이트 태양전지 및 이의 제조 방법
EP4293043A4 (en) * 2021-02-10 2025-09-10 Shanghai Genbase Biotechnology Co Ltd EPITOPE PEPTIDE OF THE RAS G13D MUTANT AND T LYMPHOCYTE RECEPTOR RECOGNIZING THE RAS G13D MUTANT
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
EP4522192A2 (en) * 2022-05-12 2025-03-19 The Johns Hopkins University Neoantigen vaccines for cancer prevention
JP2025538524A (ja) * 2022-11-22 2025-11-28 エリクサージェン セラピューティクス,インコーポレイティド 癌免疫療法のための抗原

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
AU2003301021C1 (en) 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
PL1760089T3 (pl) 2005-09-05 2010-03-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
CN101448848B (zh) * 2006-03-27 2013-12-04 全球免疫股份有限公司 Ras突变及其相关组合物和方法
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US9775892B2 (en) 2013-12-09 2017-10-03 Targovax Asa Peptide mixture
CN106414493A (zh) 2014-05-06 2017-02-15 塔格瓦克斯公司 包含突变的ras肽和化疗剂的肽疫苗

Also Published As

Publication number Publication date
BR112016013138A2 (pt) 2018-01-16
US10335473B2 (en) 2019-07-02
JP2020023525A (ja) 2020-02-13
CL2018000226A1 (es) 2018-06-22
PT3079715T (pt) 2018-08-02
US20170189515A1 (en) 2017-07-06
EP3079715B1 (en) 2018-06-13
AU2014363643A1 (en) 2016-07-14
AU2014363643B2 (en) 2019-01-03
KR20160097290A (ko) 2016-08-17
US20180021419A1 (en) 2018-01-25
JP6781403B2 (ja) 2020-11-04
LT3079715T (lt) 2018-08-27
RS57623B1 (sr) 2018-11-30
EP3363458A2 (en) 2018-08-22
EP3363457A1 (en) 2018-08-22
US10456457B2 (en) 2019-10-29
IL246007B1 (en) 2023-01-01
CY1120578T1 (el) 2019-07-10
CN105980403A (zh) 2016-09-28
SG10201811172PA (en) 2019-01-30
WO2015086590A2 (en) 2015-06-18
WO2015086590A3 (en) 2015-07-30
US10596239B2 (en) 2020-03-24
MX2016007429A (es) 2016-11-11
CL2018000238A1 (es) 2018-06-22
HUE039840T2 (hu) 2019-02-28
JP2017502081A (ja) 2017-01-19
US20160331820A1 (en) 2016-11-17
EP3369432A1 (en) 2018-09-05
AU2019201937A1 (en) 2019-04-11
SI3079715T1 (en) 2018-08-31
CA2933126A1 (en) 2015-06-18
SG11201604644QA (en) 2016-07-28
PL3079715T3 (pl) 2018-11-30
EP3079715A2 (en) 2016-10-19
CL2018000232A1 (es) 2018-06-22
IL246007A (en) 2016-07-31
RU2016127327A (ru) 2018-01-23
AU2019201937B2 (en) 2020-05-28
EP3363458A3 (en) 2018-11-07
CL2016001405A1 (es) 2017-03-24
US9775892B2 (en) 2017-10-03
ES2682038T3 (es) 2018-09-18
EP3357505A1 (en) 2018-08-08
US20170326218A1 (en) 2017-11-16
DK3079715T3 (en) 2018-09-17
IL246007B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
IL284301A (en) Heterodimeric proteins
HRP20181213T1 (hr) Peptidna smjesa
PL3004155T3 (pl) Związek peptydowy
EP3021720A4 (en) MIXER
DK3033102T4 (da) Peptidkonjugerede partikler
DK3052140T3 (da) Ikke-selvklæbende coatingmaterialer
EP2989885A4 (en) HARVESTER
DK3521423T3 (da) Manipulerede phenylalaninammoniaklyase-polypeptider
DK3041857T3 (da) Protein a-kromatografi
LT3030259T (lt) Peptidai
EP2976353A4 (en) Autophagy-inducing peptide analogs
EP3012307A4 (en) MIXED REFRIGERANT
ZA201504986B (en) Peptide
PL3061771T3 (pl) Nowy peptyd o czterech połączonych epitopach dla ctl
ZA201504987B (en) Peptide
EP3047192A4 (en) LOCKABLE LOCATED CONNECTOR
DK3004134T3 (da) Peptid-ligering
DK2983690T3 (da) Neuropeptid Y-afledte peptider
CL2016000836A1 (es) Composiciones de péptidos nuevas.
FR3014440B1 (fr) Polypeptides entomotoxiques
TH1501003671A (th) สารผสม
TH1501003672A (th) สารผสม
FI10100U1 (fi) Täyttösuppilo
TH1401006013A (th) สิ่งผสมเมอร์แคพโตไซเลน-คาร์บอนแบล็ค
UA28357S (uk) Шифер